BRPI0720236A2 - PHARMACEUTICALLY ACCEPTABLE COMPOUND OR SALT OF THE SAME, PROCESS TO PREPARE THEREOF, USE OF A COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, METHOD TO TREAT A BACTERIAL INFECTION IN A HOT BLOOD ANIMAL AS HUMAN, BEING HUMAN, - Google Patents

PHARMACEUTICALLY ACCEPTABLE COMPOUND OR SALT OF THE SAME, PROCESS TO PREPARE THEREOF, USE OF A COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, METHOD TO TREAT A BACTERIAL INFECTION IN A HOT BLOOD ANIMAL AS HUMAN, BEING HUMAN,

Info

Publication number
BRPI0720236A2
BRPI0720236A2 BRPI0720236-9A2A BRPI0720236A BRPI0720236A2 BR PI0720236 A2 BRPI0720236 A2 BR PI0720236A2 BR PI0720236 A BRPI0720236 A BR PI0720236A BR PI0720236 A2 BRPI0720236 A2 BR PI0720236A2
Authority
BR
Brazil
Prior art keywords
human
pharmaceutically acceptable
same
compound
salt
Prior art date
Application number
BRPI0720236-9A2A
Other languages
Portuguese (pt)
Inventor
Janelle Comita-Prevoir
Mark Cronin
Bolin Geng
Andrew Aydon Godfrey
Folkert Reck
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39046831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0720236(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0720236A2 publication Critical patent/BRPI0720236A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0720236-9A2A 2006-12-15 2007-12-13 PHARMACEUTICALLY ACCEPTABLE COMPOUND OR SALT OF THE SAME, PROCESS TO PREPARE THEREOF, USE OF A COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, METHOD TO TREAT A BACTERIAL INFECTION IN A HOT BLOOD ANIMAL AS HUMAN, BEING HUMAN, BRPI0720236A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87018106P 2006-12-15 2006-12-15
US96916307P 2007-08-30 2007-08-30
PCT/GB2007/004766 WO2008071961A1 (en) 2006-12-15 2007-12-13 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents

Publications (1)

Publication Number Publication Date
BRPI0720236A2 true BRPI0720236A2 (en) 2013-12-24

Family

ID=39046831

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720236-9A2A BRPI0720236A2 (en) 2006-12-15 2007-12-13 PHARMACEUTICALLY ACCEPTABLE COMPOUND OR SALT OF THE SAME, PROCESS TO PREPARE THEREOF, USE OF A COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, METHOD TO TREAT A BACTERIAL INFECTION IN A HOT BLOOD ANIMAL AS HUMAN, BEING HUMAN,

Country Status (17)

Country Link
EP (1) EP2121702A1 (en)
JP (1) JP2010513255A (en)
KR (1) KR20090090385A (en)
AR (1) AR064369A1 (en)
AU (1) AU2007331247B2 (en)
BR (1) BRPI0720236A2 (en)
CA (1) CA2671485A1 (en)
CL (1) CL2007003641A1 (en)
CO (1) CO6190619A2 (en)
EC (1) ECSP099506A (en)
MX (1) MX2009006325A (en)
NO (1) NO20092655L (en)
PE (1) PE20081511A1 (en)
RU (1) RU2009126731A (en)
TW (1) TW200831517A (en)
UY (1) UY30788A1 (en)
WO (1) WO2008071961A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
JP5398984B2 (en) 2005-06-24 2014-01-29 富山化学工業株式会社 Novel nitrogen-containing heterocyclic compounds and salts thereof
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
ES2628091T3 (en) 2008-10-10 2017-08-01 Idorsia Pharmaceuticals Ltd Oxazolidinyl antibiotics
AR076222A1 (en) 2009-04-09 2011-05-26 Actelion Pharmaceuticals Ltd DERIVATIVES 2-HYDROXIETIL-1H-QUINOLIN-ONA AND ITS AZAISOTHERAL ANALOGS WITH ANTIBACTERIAL ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2813080A1 (en) * 2010-10-04 2012-04-12 British Columbia Cancer Agency Branch Detection of fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer
CN111132976B (en) 2017-08-21 2023-08-22 阿卡蒂亚药品公司 Compounds, salts thereof and methods for treating diseases
EP3672960A2 (en) * 2017-08-21 2020-07-01 Acadia Pharmaceuticals Inc. Compounds, salts thereof and their use for the treatment of diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19601265A1 (en) * 1996-01-16 1997-07-17 Bayer Ag 2-oxo and 2-thio-1,2-dihydroquinolinyl oxazolidinones
AR040336A1 (en) 2002-06-26 2005-03-30 Glaxo Group Ltd PIPERIDINE COMPOUND, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCEDURE TO PREPARE SUCH COMPOUND
JP5314244B2 (en) * 2004-10-27 2013-10-16 富山化学工業株式会社 Novel nitrogen-containing heterocyclic compounds and salts thereof
MY150958A (en) * 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
JP5398984B2 (en) * 2005-06-24 2014-01-29 富山化学工業株式会社 Novel nitrogen-containing heterocyclic compounds and salts thereof
WO2007138974A1 (en) * 2006-05-26 2007-12-06 Toyama Chemical Co., Ltd. Novel heterocyclic compound or salt thereof and intermediate thereof
EP2029612A1 (en) * 2006-06-09 2009-03-04 Glaxo Group Limited Substituted 1-methyl-1h-quinolin-2-ones and 1-methyl-1h-1,5-naphthyridin-2-ones as antibacterials
GB0613208D0 (en) * 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
NZ573644A (en) * 2006-07-20 2011-09-30 Glaxo Group Ltd Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
EP1992628A1 (en) * 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones

Also Published As

Publication number Publication date
CA2671485A1 (en) 2008-06-19
EP2121702A1 (en) 2009-11-25
RU2009126731A (en) 2011-01-20
AR064369A1 (en) 2009-04-01
WO2008071961A8 (en) 2009-10-22
CL2007003641A1 (en) 2008-09-22
AU2007331247A1 (en) 2008-06-19
JP2010513255A (en) 2010-04-30
NO20092655L (en) 2009-09-02
WO2008071961A1 (en) 2008-06-19
AU2007331247B2 (en) 2011-10-20
TW200831517A (en) 2008-08-01
CO6190619A2 (en) 2010-08-19
PE20081511A1 (en) 2008-12-12
UY30788A1 (en) 2008-07-31
MX2009006325A (en) 2009-07-24
KR20090090385A (en) 2009-08-25
ECSP099506A (en) 2009-08-28

Similar Documents

Publication Publication Date Title
BRPI0920180A2 (en) COMPOUND, USE OF A COMPOUND, METHOD FOR TREATING A BACTERIAL INFECTION IN A HOT BLOOD ANIMAL, PHARMACEUTICAL COMPOSITION, AND, PROCESS FOR PREPARING A COMPOUND
BRPI0811534A2 (en) COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, USE OF A COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, METHOD FOR TREATING CANCER IN A BLOOD ANIMAL, AND PROCESS TO MAKE A PHARMACEUTICAL COMPLETE SALT.
BRPI0720236A2 (en) PHARMACEUTICALLY ACCEPTABLE COMPOUND OR SALT OF THE SAME, PROCESS TO PREPARE THEREOF, USE OF A COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME, METHOD TO TREAT A BACTERIAL INFECTION IN A HOT BLOOD ANIMAL AS HUMAN, BEING HUMAN,
BRPI0813427A2 (en) COMPOUND, USE OF THE SAME, METHOD TO TREAT BACTERIAL INFECTION IN A HOT BLOOD ANIMAL, PHARMACEUTICAL COMPOSITION, AND PROCESS FOR PREPARING A COMPOUND.
BRPI0812738A2 (en) COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD FOR THE TREATMENT OF A VIRAL INFECTION IN A HUMAN
BRPI1009860A2 (en) compound, use thereof, pharmaceutical composition and method for the therapeutic treatment or prevention of disease in humans or animals
BRPI0812473A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS FOR INHIBITING BACTERIAL DNA GYRASE AND / OR BACTERIAL TOPOISOMERASE IV IN A HOT BLOOD ANIMAL IN SUCH TREATMENT, TO PRODUCE AN ANTIBACTERIAL EFFECT ON A BLOOD ANIMAL TREATMENT BACTERIAL INFECTION IN A HOT BLOOD ANIMAL IN NEED OF THE SAME, USE OF A COMPOUND, AND PROCESS TO PREPARE A COMPOUND
CL2007003472A1 (en) SMOKE SALT OF (ALFA S, BETA R) -6-BROMO-ALFA- [2- (DIMETILAMINO) ETIL] -2-METOXI-ALFA-1-NAFTALENIL-BETA-PHENYL-3-QUINOLINAETHANOL; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PHARMACEUTICAL COMPOSITION PREPARATION PROCESS; AND USE IN THE TREATMENT
BRPI0820568A2 (en) Compound, pharmaceutical composition, use of a compound or pharmaceutical composition, and method of treating a human or animal
BRPI0812851A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT OF A DISEASE AND CONDITION IN AN INDIVIDUAL, PROCESS FOR PREPARING A COMPOUND, AND USE OF A COMPOUND
WO2009026166A3 (en) Antiinfective flavonol compounds and methods of use thereof
BR112012033117A2 (en) pyrazolo [1,5-a] pyrimidines as antiviral agents
BRPI0913300A2 (en) compound, process for preparation and use thereof, method of treating bacterial infection in an animal, and pharmaceutical composition.
BRPI0813450A2 (en) COMPOUND, COMPOSITION, COMBINATION, PHARMACEUTICAL FORMULATION, AND METHODS TO INHIBIT AN ENZYME, TO EXTERMINE OR PREVENT GROWTH OF A MICROORGANISM, AND TO TREAT AND / OR PREVENT A DISEASE IN AN ANIMAL
BRPI0811436A2 (en) COMPOUND, USE OF A COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHODS FOR PAIN THERAPY IN A HOT BLOOD ANIMAL, SUPER ACTIVE BLADDER THERAPY IN A HOT BLOOD ANIMAL, AND TO PREPARE A COMPOUND.
BRPI0909447A2 (en) Composition, methods for treating a human or animal subject in need of such treatment and for killing or inhibiting the growth of susceptible microorganisms, and use of a composition.
BR112013030045A2 (en) compound of the formula d-m-d or a pharmaceutically acceptable salt thereof; compound or salt; pharmaceutical composition; and method of treating hepatitis c infection in a patient
BRPI0615157A2 (en) compound, pharmaceutical composition, methods for inhibiting viral replication in a human patient, and for treating a viral infection in a human patient, and use of a compound
BR112012003578A2 (en) compound, pharmaceutically acceptable salt, sulfate salt, pharmaceutical composition, method for treating a viral infection, and use of a compound or salt.
BR112012005225B8 (en) USE OF AN ACTRIIB-FC FUSION PROTEIN FOR THE TREATMENT OF A DISORDER RELATED TO BONE OR ASSOCIATED WITH MUSCLE LOSS DUE TO FAULT MUSCLE GROWTH
BRPI0822162A2 (en) Method for treating nail or nail bed disease and pharmaceutical composition for topical treatment of nail or nail bed disease.
BRPI0906805A2 (en) Compound, process for preparing pure enanciomer, pharmaceutical composition, use of pure enanciomer, methods for preventing or treating disease in a warm-blooded animal, and combination
BR112012002246A2 (en) acceptable pharmaceutical compound, compound or salt thereof, pharmaceutical composition, method for inhibiting, treating and / or reducing cognitive decline and / or akzhmer's disease in a patient
BR112012021522A2 (en) orthodontic bracket for an orthodontic system, orthodontic bracket system, orthodontic kit, process for making an orthodontic bracket and method for treating a human patient's bite
BRPI1012066A2 (en) oral care composition, and methods for preparing the oral care composition and for administering a zinc compound to an animal or human individual in need thereof

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2277 DE 26/08/2014.